EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER
HBV Endpoints 20198-9 March 2019 London
N. Poster
Poster title
Applicant name
Status
 |
|
|
|
| P01-01 | In vitro and in vivo models of hepatitis B virus (HBV) replication utilising monomeric HBV genomes to facilitate studies of the HBV cccDNA minichromosome. | Peter Revill |  Received |
 |
|||
| P03-01 | Evaluation of the Safety and Tolerability of Transaminase Flares During Antiviral Therapy in Patients with HBeAg Negative Chronic HBV Infection or HBV / HDV Co-infection | Andrew Vaillant | Received |
|
|||
| P04-01 | Hepatitis B core-related antigen quantification is an accurate predictor 12-months prior to hepatitis B e antigen-seroclearance in human immunodeficiency virus/hepatitis B coinfected patients treated with tenofovir | Lorenza Dezanet | Received |
|
|||
| OP-01 | A novel pyrazole HBV nucleocapsid formation inhibitor demonstrating high activity against HBV variants that are resistant to class I and class II core protein allosteric modulators | Zhijun Zhang | Received |
|
|||
| P06-01 | Hepatitis B virus infection as a trigger of hepatocyte identity loss | Chloe Goldsmith | Received |
|
|||
| P04-02 | Anti-hepatitis B core antibody titer and interleukin-10 quantification as predictors of hepatitis B e antigen-seroclearance in human immunodeficiency virus/hepatitis B coinfected patients treated with tenofovir | Lorenza Dezanet | Received |
|
|||
| P06-02 | Serum M2BPGi as a diagnostic marker of liver fibrosis in patients with chronic hepatitis B | Natthaya Chuaypen | Received |
|
|||
| P03-02 | Efficient Clinical Development of More Curative HBV Therapies | Nathaniel Brown | Received |
|
|||
| OP-02 | Establishment of High Rates of Functional Cure of HBeAg Negative Chronic HBV Infection with REP 2139-Mg Based Combination Therapy: Ongoing Follow-up Results from the REP 401 Study | Andrew Vaillant | Received |
|
|||
| P01-03 | HBV RNA at 6 months predicts HBeAg loss in nucleos(t)ide analogue treated HBeAg positive patients: demonstration of clinical utility? | Bo Wang | Received |
|
|||
| P06-03 | Association between Hepatitis B Virus preS2 deletion and increased risk of Hepatocellular Carcinoma: a case-control study in West Africa | Damien Cohen | Received |
|
|||
| P03-03 | Prediction of HBeAg loss on long-term nucleos(t)ide analogues with a novel HBV pgRNA assay | Daryl Lau | Received |
|
|||
| P04-03 | Serum HBV RNA and HBcrAg: new markers for predicting incomplete HBV DNA suppression after initiation of nucleoside therapy in HIV/HBV co-infected individuals. | Ruth Byrne | Received |
|
|||
| OP-03 | Pre-genomic HBV RNA and HBcrAg play important role in the predicting clinical outcomes in chronic hepatitis B patients suppressed on antiviral therapy with nucleos(t)ide analogues | Ivana Carey | Received |
|
|||
| P02-03 | The gamma glutamyl transpeptidase to platelets ratio and gamma glutamyl transpeptidase to albumin ratio do not correlate to fibroscan measurement of hepatic fibrosis in chronic hepatitis b egyptian patients: a pilot study | Mohammed Elhendawy | Received |
|
|||
| OP-04 | Hepatitis B core-related antigen correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients | Barbara Testoni | Received |
|
|||
| P02-04 | Core outcome set for Cochrane reviews on chronic hepatitis B infection | Mirella Fraquelli | Received |
|
|||
| P01-04 | Dynamic changes of serum HBV pgRNA levels in patients with chronic hepatitis B treated with entecavir or peg-interferon | Xiaoqi Yu | Received |
|
|||
| P04-04 | Genetic variation in STAT4 is associated with treatment response to pegylated interferon in patients with chronic hepatitis B | Natthaya Chuaypen | Received |
|
|||
| P06-04 | The effect of diabetes mellitus on treatment course of chronic hepatitis B and their clinical profile | Ibtehaj Alharbi | Received |
|
|||
| P03-04 | Diagnostic accuracy of aspartate transaminase to platelet ratio index ,fibrosis index based on 4 factors (fib-4) and golgi protein 73 for prediction of significant liver fibrosis in chronic hepatitis b patients:an egyptian cross-sectional study | Rahma Mohamed | Received |
|
|||
| P02-05 | outcomes of severe acute viral hepatitis b in latvia | Jekaterina Kucina | Received |
|
|||
| P04-05 | Evaluation of serum alanine aminotransferase level in treated chronic hepatitis B patients | Wanna Yang | Received |
|
|||
| P03-05 | Serum sulfatase-2 is a new prognostic marker of patients with hepatitis B Virus-related hepatocellular carcinoma | Natthaya Chuaypen | Received |
|
|||
| P01-05 | Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review | Raquel Scherer de Fraga | Received |
|
|||
| P06-05 | Mean Week 24 HBsAg declines predict subsequent rate of HBsAg seroclearance and could be a valuable endpoint for early development hepatitis B virus trials | Gail Edwards | Received |
|
|||
| OP-05 | TherVac B - an optimized therapeutic vaccine for hepatitis B | Ulrike Protzer | Received |
|
|||
| OP-06 | Investigating the role of HBsAg on cellular immune responses in HBeAg negative patients with chronic hepatitis B to define HBV treatment endpoints | Elmira Aliabadi | Received |
|
|||
HBV Endpoints 2019
8-9 March 2019 London
Search and consult posters online
in an exclusive section
for each poster
in an exclusive section
for each poster
ACTIVE FROM 08/03/2019 TO 08/03/2020
Poster
Gallery
Gallery
Upload
Poster
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
Forum
|
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.
|
|
||
|
||||
|
|
